Enalare Therapeutics
Health Care
$12.5Mlatest round · Venture round · Aug 2022 · 4 yr ago
$2.8Mgrants · 2 grants · CORDIS
50+team · employees, estimated range
19stories in the press
Overview
ENALARE THERAPEUTICS. Our lead drug candidate, ENA-001, is a patent-protected new chemical entity (NCE) beginning additional clinical trials in the fourth quarter of 2021.
Funding and backers
Total raised
$12.5M
4 rounds on record
Latest round
$12.5M
Venture round · Aug 2022 · 4 yr ago
Team
51-200
employees, estimated range
Grants
$2.8M
2 grants · CORDIS
The money's age
Long since its last round
50 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jan 1, 2025
Won a grant $2.5M · CORDIS
Jul 1, 2022
Won a grant $320k · CORDIS
Feb 7, 2022
Took on debt financing $1M · SEC Form D
Feb 7, 2022
Board appointment Mark Coleman, Director · SEC Form D
Nov 9, 2020
New executive Enalare Therapeutics Appoints Daniel Motto as Chief Business Officer · newswire.com
2018
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Grant | Jan 2025 | $2.5M | — | CORDIS |
| Venture round | Aug 2022 | $12.5M | — | SEC Form D |
| Grant | Jul 2022 | $320k | — | CORDIS |
| Debt Financing | Feb 2022 | $1M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Enalare Therapeutics Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Joseph PergolizziExecutive Officer, DirectorSEC Form D
Herman CukierExecutive Officer, DirectorSEC Form D
Daniel MottoExecutive OfficerSEC Form D
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Helping you uncover why drug candidates fail before clinical trials even start. Order TMEmic today!
Avigen develops cellular avidity tools for immunotherapy and cell therapy R&D, helping identify potent and safe lead drug candidates faster.
For more than 25 years, Banook provides Clinical Trials Response to inhance clinical trials performances.
About Us. BeTagged started operations in 2019 and further deepened its commitment by launching an Influencer marketing platform in the last…
Quris AI is tackling the most impactful AI challenge of our time: Predicting which drug candidates will safely work in humans. Quris’s…
Opna Bio is a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics. The…
People
Joseph Pergolizzi
Executive Officer, Director
Herman Cukier
Executive Officer, Director
Daniel Motto
Executive Officer
Gino Santini
Director
Joseph Petko
Director
Robert Yedid
Director
Mark Coleman
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
News
Enalare Therapeutics Receives Second Component of a National Institutes of Health (NIH) Grant Award to Fund the Next Human Study of ENA-001
Enalare Therapeutics Inc., a biopharmaceutical company dedicated to developing novel therapies for patients suffering from life threatening critical care conditions and national health emergencies, announced today that it has been awarded the second ...
Read more
Report
Enalare Therapeutics is Granted a New Patent for ENA-001, Extending Its Exclusivity in the U.S. to 2043
The New Patent Covers ENA-001 Methods of Treating Respiratory Depression Caused by Propofol, a Widely Used, Centrally Acting AnestheticPRINCETON, NJ / ACCESSWIRE / November 14, 2024 / Enalare Therapeutics
Read more
Report
Enalare Therapeutics Receives Additional Funding From BARDA to Further Advance the Development of Agnostic Respiratory Stimulant (ENA-001)
Read more
Report
Enalare Therapeutics Announces Publication of a Clinical Study Demonstrating the Effect of ENA-001 on Improving Propofol-Induced Depression of the Hypoxic Ventilatory Response
Enalare Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to developing novel compounds for the treatment of life-threatenin ...
Read more
Report
Report
Enalare Therapeutics Selected to Present at Three Upcoming Scientific Conferences Regarding Its Lead Compound, ENA-001
PRINCETON, NJ / ACCESSWIRE / August 22, 2023 / Enalare Therapeutics Inc., a clinical stage biopharmaceutical company dedicated to developing novel compounds for the treatment of life- threatening critical
Read more
Report
Enalare Therapeutics Nominated for Two Citeline Awards in Recognition of Outstanding Clinical Efforts
Enalare Therapeutics Inc., a clinical stage biopharmaceutical company dedicated to developing novel compounds for the treatment of life-threaten ...
Read more
Report
Eagle Pharmaceuticals and Enalare Therapeutics Announce FDA Orphan Drug Designation for ENA-001 for the Treatment of Apnea of Prematurity, a New Chemical Entity Being Developed as an Agnostic Respiratory Stimulant
-- ENA-001, with a novel mechanism of action as an agnostic respiratory stimulant, has previously been granted Rare Pediatric Disease Designation for the treatment of Apnea of Prematurity by the FDA with eligibility for a priority review voucher -- -- The
Read more
Report
Enalare Therapeutics Receives an Additional Award Worth Up to $50 Million From BARDA, Expanding Its Partnership in Development of ENA-001
The Funding Will Accelerate Development of an Intramuscular Formulation of ENA-001, a Novel Agnostic Respiratory Stimulant, for the Potential Treatment of Community Drug Overdose and as a Medical Countermeasure for Mass Casualty Events. The Funding Suppor
Read more
Report
Enalare Therapeutics Announces Positive Topline Results With ENA001 in a Propofol Induced Respiratory Depression Study
ENA001, an Agnostic Respiratory Stimulant, Successfully Achieved the Study Primary Endpoint and Was Shown to Be Safe and Well Tolerated
Read more
Report
Show more news
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Princeton
United States
HQ
50-200 est. staff